XKRX144510
Market cap235mUSD
Dec 27, Last price
23,100.00KRW
1D
-1.91%
1Q
-28.04%
Jan 2017
-7.41%
IPO
-63.04%
Name
GC Cell Corp
Chart & Performance
P/E
—
P/S
1.85
EPS
—
Div Yield, %
1.51%
Shrs. gr., 5y
—
Rev. gr., 5y
10.92%
Revenues
187.54b
-20.57%
Net income
-174m
L
CFO
3.67b
-94.47%
Dividend
Dec 27, 2023350 KRW/sh
Earnings
Jan 29, 2025
Profile
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 187,544,189 -20.57% | 236,120,073 40.29% | 168,309,997 96.71% | ||
Cost of revenue | 166,850,731 | 173,511,789 | 123,621,802 | ||
Unusual Expense (Income) | |||||
NOPBT | 20,693,458 | 62,608,284 | 44,688,195 | ||
NOPBT Margin | 11.03% | 26.52% | 26.55% | ||
Operating Taxes | (7,542,669) | 10,793,032 | 9,469,201 | ||
Tax Rate | 17.24% | 21.19% | |||
NOPAT | 28,236,127 | 51,815,252 | 35,218,994 | ||
Net income | (174,010) -100.70% | 24,990,846 -20.47% | 31,421,670 655.31% | ||
Dividends | (5,254,325) | (1,055,405) | |||
Dividend yield | 0.77% | 0.09% | |||
Proceeds from repurchase of equity | (545) | 3,643,516 | (43,597,790) | ||
BB yield | 0.00% | -0.51% | 3.80% | ||
| Debt | |||||
Debt current | 50,759,180 | 44,642,756 | 37,879,669 | ||
Long-term debt | 82,492,895 | 64,847,162 | 59,125,593 | ||
Deferred revenue | 11,020,820 | 12,849,482 | |||
Other long-term liabilities | 6,204,730 | 560 | 490 | ||
Net debt | 81,260,395 | 12,913,409 | 67,168,575 | ||
| Cash flow | |||||
Cash from operating activities | 3,670,712 | 66,415,193 | 23,907,829 | ||
CAPEX | (18,397,037) | (13,778,835) | (13,719,791) | ||
Cash from investing activities | (34,301,189) | (33,723,922) | 17,285,047 | ||
Cash from financing activities | (4,062,058) | (3,321,923) | (32,389,611) | ||
FCF | (1,988,919) | 74,190,716 | (88,944,275) | ||
| Balance | |||||
Cash | 12,557,663 | 47,374,244 | 20,009,099 | ||
Long term investments | 39,434,017 | 49,202,266 | 9,827,587 | ||
Excess cash | 42,614,470 | 84,770,506 | 21,421,186 | ||
Stockholders' equity | 124,182,259 | 130,953,512 | 50,879,582 | ||
Invested Capital | 589,041,479 | 540,739,714 | 563,179,612 | ||
ROIC | 5.00% | 9.39% | 11.72% | ||
ROCE | 3.24% | 9.99% | 7.63% | ||
| EV | |||||
Common stock shares outstanding | 15,022 | 15,028 | 11,287 | ||
Price | 45,500.00 -3.50% | 47,150.00 -53.64% | 101,700.00 10.42% | ||
Market cap | 683,480,844 -3.54% | 708,549,831 -38.27% | 1,147,838,982 18.04% | ||
EV | 772,201,814 | 728,751,969 | 1,219,687,752 | ||
EBITDA | 36,332,815 | 76,231,060 | 52,083,514 | ||
EV/EBITDA | 21.25 | 9.56 | 23.42 | ||
Interest | 3,408,551 | 2,481,239 | 559,038 | ||
Interest/NOPBT | 16.47% | 3.96% | 1.25% | ||